Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 51 - 100 out of 46,195

Document Document Title
WO/2014/122530
Embodiments of the present invention relate to 4-(phenoxymethyl)-1,3-dioxolane analogs and pharmaceutical compositions thereof having a disease-modifying action in the treatment of diseases associated with the overproduction of Cortisol ...  
WO/2014/120784
Disclosed are compounds having enhanced potency in the modulation of NMD A receptor activity. Such compounds are contemplated for use in the treatment of conditions such as depression and related disorders. Orally available formulations ...  
WO/2014/120800
Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of conditions such as depression and related disorders. Orally available formulations a...  
WO/2014/120786
Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of conditions such as depression and related disorders. Orally available formulations a...  
WO/2014/121062
Provided herein are HDAC3 inhibitors, as well as methods of treatment comprising administering these compounds to a subject in need thereof.  
WO/2014/120783
Disclosed are compounds having enhanced potency in the modulation of NMD A receptor activity. Such compounds are contemplated for use in the treatment of conditions such as depression and related disorders. Orally available formulations ...  
WO/2014/118039
The present invention relates to radiolabeled compounds of formula (I) wherein R1, R2, R3 and R4 are as defined herein.  
WO/2014/117947
The invention relates to novel substituted condensed pyrimidine compounds of general formula (I) in which the chemical groupings, substituents and indices are as defined in the description, and to their use as medicaments, in particular ...  
WO/2014/120789
Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of conditions such as depression and related disorders. Orally available formulations a...  
WO/2014/120885
The present invention relates to the field of drug abuse. More specifically, the present invention provides methods and compositions for treating drug abuse by preventing GAPDH nitrosylation. In one specific embodiment, a method for prev...  
WO/2014/117700
The present invention provides a protopanoxadiol derivative of structural formula I or II, a preparation method and an application thereof. The present invention performs structural modification on protopanoxadiol, and obtains multiple n...  
WO/2014/119649
 The objective of the present invention is to provide a compound, or a salt thereof, having regulatory activity on the function of lysophosphatidylserine receptors. The present invention provides a compound, or a salt thereof, having...  
WO/2014/117919
The present invention relates to novel substituted pyridine derivatives as positive allosteric modulators for modulating metabotropic giutamate receptor subtype 3 (mGluR3) and/or altering giutamate level or glutamatergic signalling.  
WO/2014/117669
Disclosed is a benzisoselenazolone-containing donepezil analog as represented by formula I and in either the form of a free radical, the form of a salt or the form of a solvate, also disclosed are a pharmaceutical composition comprising ...  
WO/2014/118133
The present invention relates to new kinase inhibitors of Formula (I) or a stereoisomer, tautomer, racemic, salt, hydrate, or solvate thereof, and more specifically to ROCK inhibitors, compositions, in particular pharmaceuticals, compris...  
WO/2014/117670
The present application provides a styryl quinoline compound represented by formula I and the use thereof in a pharmaceutical composition for treating, improving, and/or preventing Alzheimer's disease. R1-R7 are as defined in the descrip...  
WO/2014/120658
The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: wherein variables A5, A6, A8, R1, R2, R3, R7, X, Y, n and o of Formula I,...  
WO/2014/118307
The present invention relates to novel crystal forms of 4-(6-ethoxy-1-methoxy-thioxanthene-9-ylidcne)-1-methyl piperidine salts and 4-(6-ethoxy-1-hydroxy-thioxanthene-9-ylidene)-1-methyl piperidine salts; especially to novel crystal form...  
WO/2014/120994
The present invention provides compounds of formula I or a salt, solvate, or stereoisomer thereof, wherein X is H, or an electron withdrawing group such as a halogen, NH2, NO2, SO2, CN, or a C1-C6 alkyl group; Alk is C1-C3 alkyl; R1 is H...  
WO/2014/117680
The invention relates to the use of TRPC6 mRNA levels in peripheral blood cells for the early detection/diagnosis of senile dementia. Specifically, the present invention provides a classic transient receptor potential channel 6 (TPRC6) g...  
WO/2014/117863
The present invention relates to novel crystal forms of 4-(6-ethoxy-l-methoxy-thioxanthene-9- ylidene)-1-methyl piperidine salts and 4-(6-ethoxy-1-hydroxy-thioxanthene-9-ylidene)-1-methyl piperidine salts; especially to novel crystal for...  
WO/2014/120654
The present invention relates to new benzoquinolone inhibitors of VMAT2, pharmaceutical compositions thereof, and methods of use thereof.  
WO/2014/120815
The invention relates to compounds of formula (I) or pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels: formula (I). The invention also provides pharmaceutically acceptable compositions comprising the com...  
WO/2014/117220
The present disclosure relates to proteins that bind to CD83 and uses thereof, for example, in therapy, prophylaxis, diagnosis, or prognosis.  
WO/2014/120538
Methods of treatment of multiple sclerosis (MS) with PPARγ agonists, and in particular with the compound of formula (I) known as INT131.  
WO/2014/115885
 The present invention provides a novel therapeutic agent for demyelinating disease which acts to suppress the demyelination of the neuroaxis. The present invention provides a therapeutic agent for demyelinating disease, the therapeuti...  
WO/2014/117089
A method of treating a pervasive development disorder in a subject includes administering to the subject an amount of an NMDAR antagonist effective to ameliorate biochemical and functional abnormalities in the subject associated with los...  
WO/2014/116652  
WO/2014/116015
The present invention provides a functional composition for preventing Alzheimer's disease, containing a heat-treatment salt heat treated at 800-1,200℃ as an active ingredient, and other pharmaceutically or cytologically acceptable ing...  
WO/2014/116666
The present disclosure provides methods and kits for treating and classifying individuals at risk of or suffering from a neurological dysfunction or disorder. In general, the individuals are treated and/or classified based on the presenc...  
WO/2014/115072
The invention relates to heterocyclic amide derivatives of formula (I), wherein R1, R2, R3, R4, R5, n, m, p and X are as defined in the description, their preparation and their use as pharmaceutically active compounds.  
WO/2014/114248
The present invention relates to novel 3,4-dihydro-1H-pyrimido[1,6-a]pyrimidin-6(2H)-one compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of disea...  
WO/2014/114532
The present invention provides a compound of formula I having BACE1 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the prese...  
WO/2014/116132
Mammalian central nervous system (CNS) neurons do not regenerate after injury due to the inhibitory environment formed by the glial scar, largely constituted by myelin debris. The use of biomaterials to bridge the lesion area and the cre...  
WO/2014/114186
The present invention belongs to the field of pharmaceutical techniques, and in particular relates to JNK inhibitors as shown by general formulae (I), (1a) or (1b), pharmaceutically acceptable salts or stereoisomers thereof, the preparat...  
WO/2014/114694
The present invention relates to novel compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for e...  
WO/2014/114742
A compound of formula (I) in which the dotted lines indicate the presence of at least one double bond; n = 0 to 4; R3 and R4 are H, or when n = 1, R3 and R4 can also form together a double bond between the carbon atoms, and m = 0, 1 or 2...  
WO/2014/116739
Compositions of L-4-chlorokynurenine are provided, as are methods for the treatment of neurological dysfunction.  
WO/2014/113878
A method is disclosed to dissolve protein deposited in muscle. The method includes the step of administering an effective amount of an agent selected from the group consisting of fibrinolytics, proteolytics, photolytic and magnelytic age...  
WO/2014/115853
The propellane derivatives represented by general formula (I) or pharmaceutically-acceptable acid addition salts thereof, or hydrates or solvates of said propellane derivatives and acid addition salts are used as analgesics, antidepressa...  
WO/2014/115098
The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount ...  
WO/2014/117176
The present invention relates in some aspects to compositions (e.g., pharmaceutical, nutritional compositions, etc.), formulations, and food or beverage products comprising, consisting essentially of, or consisting of (a) β-alanine or a...  
WO/2014/114779
The present invention is directed to N-substituted-5-substituted phthalamic acids which of formula (A). The compounds are considered useful for the treatment of diseases treatment of a neurodegenerative disease, psychiatric disease, moto...  
WO/2014/115430
The present invention provides: a humanized anti-HMGB1 antibody that binds specifically to a sequence consisting of an eight-amino-acid residue (EEEDDDDE) at the C terminal of the HMGB1 protein, and that is effective in the treatment or ...  
WO/2014/113844
The present invention relates to the field of biomarkers and in particular to their utilisation in treatment. Embodiments of the invention have been particularly developed as biomarkers enabling optimisation of treatment regimes and as u...  
WO/2014/114032
A non-addictive analgesic sustained-release drug delivery system, comprising: (1) a narcotic analgesic drug having a concentration of 1 mg/ml-160 mg/ml, the drug being selected from a group consisting of: a local analgesic drug, and the ...  
WO/2014/114627
The invention relates to a pharmaceutical combination of 2-aminoethanesulfonic acid with a phannaceutical agent such as an antihypertensive agent and the use of 2-aminoethanesulfonic acid in a method to lower the bilirubin level in the b...  
WO/2014/114695
The present invention relates to novel pyrimidine derivatives of formula (I)[Formula should be entered here] as inhibitors of the enzyme phosphodiesterase 10 (PDE-10), pharmaceutical compositions comprising an effective amount of these c...  
WO/2014/113750
The invention comprises novel inhibitors of dipeptidyl peptidase IV (DPP-IV) with beta blocker activity, pharmaceutical compositions comprising therapeutically effective amounts of novel inhibitors of DPP-IV, and novel methods of treatin...  
WO/2014/111457
The present invention is concerned with novel substituted pyrido-piperazinone derivatives of Formula (I) wherein R1, R2, R3, R4, R5, L, Z and X have the meaning defined in the claims. The compounds according to the present invention are ...  

Matches 51 - 100 out of 46,195